Companies Dominating the Multiple Sclerosis Drug Landscape
- Biogen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Merck KGaA.
- Janssen Pharmaceuticals Companies of Johnson & Johnson
- Bristol-Myers Squibb Company
- Cipla Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
2025 Multiple Sclerosis Drug Market is evaluated at USD 25.91 billion.
The global multiple sclerosis drug market size was worth over USD 25.07 billion in 2024 and is expected to see a CAGR exceeding 4.2%, reaching over USD 42.8 billion by 2037.
North America is set to lead, impelled by the global rise in multiple sclerosis cases, particularly among women.
The major players in the market include Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA., Janssen Pharmaceuticals Companies of Johnson & Johnson, Bristol-Myers Squibb Company, Cipla Inc.
